Bright Minds Biosciences ... (DRUG)
Bright Minds Biosciences Statistics
Share Statistics
Bright Minds Biosciences has - shares outstanding. The number of shares has increased by 57.8% in one year.
| Shares Outstanding | - |
| Shares Change (YoY) | 57.8% |
| Shares Change (QoQ) | 1.37% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 4.92M |
| Failed to Deliver (FTD) Shares | 1.36K |
| FTD / Avg. Volume | 2.18% |
Short Selling Information
The latest short interest is 221.22K, so 3.17% of the outstanding shares have been sold short.
| Short Interest | 221.22K |
| Short % of Shares Out | 3.17% |
| Short % of Float | 4.38% |
| Short Ratio (days to cover) | 1.24 |
Valuation Ratios
The PE ratio is -2.43 and the forward PE ratio is -20.2. Bright Minds Biosciences's PEG ratio is 0.04.
| PE Ratio | -2.43 |
| Forward PE | -20.2 |
| PS Ratio | 0 |
| Forward PS | 4.4 |
| PB Ratio | 1.23 |
| P/FCF Ratio | -3.69 |
| PEG Ratio | 0.04 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Bright Minds Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.32, with a Debt / Equity ratio of 0.02.
| Current Ratio | 11.32 |
| Quick Ratio | 11.32 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | - |
| Debt / FCF | -0.06 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $- |
| Profits Per Employee | $- |
| Employee Count | undefined |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 2468.46% in the last 52 weeks. The beta is 1.02, so Bright Minds Biosciences's price volatility has been higher than the market average.
| Beta | 1.02 |
| 52-Week Price Change | 2468.46% |
| 50-Day Moving Average | 36.19 |
| 200-Day Moving Average | 23.17 |
| Relative Strength Index (RSI) | 39.91 |
| Average Volume (20 Days) | 62.74K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -2.62M |
| Net Income | -2.8M |
| EBITDA | 0 |
| EBIT | -2.62M |
| Earnings Per Share (EPS) | -0.65 |
Balance Sheet
The company has 5.72M in cash and 118.96K in debt, giving a net cash position of 5.6M.
| Cash & Cash Equivalents | 5.72M |
| Total Debt | 118.96K |
| Net Cash | 5.6M |
| Retained Earnings | -34.35M |
| Total Assets | 58.4M |
| Working Capital | 57.76M |
Cash Flow
In the last 12 months, operating cash flow was -1.85M and capital expenditures 0, giving a free cash flow of -1.85M.
| Operating Cash Flow | -1.85M |
| Capital Expenditures | 0 |
| Free Cash Flow | -1.85M |
| FCF Per Share | -0.43 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DRUG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for DRUG is $85, which is 154.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $85 |
| Price Target Difference | 154.6% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Jul 14, 2023. It was a backward split with a ratio of 1:5.
| Last Split Date | Jul 14, 2023 |
| Split Type | backward |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | 267.21 |
| Piotroski F-Score | 1 |